Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19758
Title: Randomized Controlled Trial of Melatonin for Sleep Disturbance in Dravet Syndrome: The DREAMS Study.
Authors: Myers, Kenneth A;Davey, Margot J;Ching, Michael;Ellis, Colin;Grinton, Bronwyn E;Roten, Annie;Lightfoot, Paul A;Scheffer, Ingrid E
Affiliation: Melbourne Children's Sleep Centre, Monash Children's Hospital, Melbourne, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia
Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia
Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
Department of Neurology, Royal Children's Hospital, Parkville, Victoria, Australia
Departments of Pediatrics and Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
Issue Date: 15-Oct-2018
EDate: 2018-10-15
Citation: Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2018; 14(10): 1697-1704
Abstract: Dravet syndrome is a severe developmental and epileptic encephalopathy, in which 75% of patients have sleep disturbance. Melatonin is often used for sleep problems in childhood; however, there is no quality evidence supporting its use in Dravet syndrome. We hypothesized that melatonin would increase total sleep and quality of life for patients with Dravet syndrome. A double-blind crossover randomized placebo-controlled trial was conducted, comparing 6 mg regular-release melatonin to placebo for patients with Dravet syndrome and sleep disturbance. The primary outcome measure was total sleep measured by actigraphy, with secondary outcomes including wakefulness after sleep onset (WASO), Sleep Disturbance Scale in Children and Quality of Life in Children with Epilepsy 55 questionnaires, caregiver reports of clinical change, seizure diary and serum antiepileptic drug levels. We also compared actigraphy data of patients with Dravet syndrome to an age-matched healthy control group. A total of 13 patients completed the study. There was no difference in total sleep or WASO between melatonin and placebo. However, of the 11 patients for whom caregivers reported a clear clinical difference between treatments (blinded), 8 reported improvement on melatonin (P < .05). Interestingly, when compared to patients in the control group, patients with Dravet syndrome had significantly increased total sleep (P = .002). Melatonin did not increase total sleep; however, blinded caregiver reports indicate treatment with melatonin provided considerable clinical benefit for some patients with Dravet syndrome and sleep disturbance. Registry: Australian Government Department of Health, Therapeutic Goods Administration under the Clinical Trials Notification Scheme (protocol number 2241).
URI: http://ahro.austin.org.au/austinjspui/handle/1/19758
DOI: 10.5664/jcsm.7376
ORCID: 0000-0001-7831-4593
0000-0002-2311-2174
PubMed URL: 30353809
Type: Journal Article
Subjects: Dravet syndrome
actigraphy
melatonin
scn1a
sleep
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.